Department of Radiation Oncology, Sutter Medical Center, Sacramento, California.
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Pract Radiat Oncol. 2020 Jan-Feb;10(1):8-20. doi: 10.1016/j.prro.2019.10.014. Epub 2019 Dec 9.
This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).
The American Society for Radiation Oncology convened a task force to address 5 key questions focused on indications for RT in the definitive and postoperative setting for BCC and cSCC, as well as dose-fractionation schemes, target volumes, basic aspects of treatment planning, choice of radiation modality, and the role of systemic therapy in combination with radiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength.
The guideline recommends definitive RT as primary treatment for patients with BCC and cSCC who are not surgical candidates while conditionally recommending RT with an emphasis on shared decision-making in those situations in which adequate resection can lead to a less than satisfactory cosmetic or functional outcome. In the postoperative setting, a number of indications for RT after an adequate resection are provided while distinguishing the strength of the recommendations between BCC and cSCC. One key question is dedicated to defining indications for regional nodal irradiation. The task force suggests a range of appropriate dose-fractionation schemes for treatment of primary and nodal volumes in definitive and postoperative scenarios. The guideline also recommends against the use of carboplatin concurrently with adjuvant RT and conditionally recommends the use of systemic therapies for unresectable primaries where treatment may need escalation.
Defining the role of RT in the management of BCC and cSCC has been hindered by a lack of high-quality evidence. This document synthesizes available evidence to define practice guidelines for the most common clinical situations. We encourage practitioners to enroll patients in prospective trials and to approach care in a multidisciplinary fashion whenever possible.
本指南回顾了在基底细胞癌(BCC)和皮肤鳞状细胞癌(cSCC)患者中使用确定性和术后放射治疗(RT)的证据。
美国放射肿瘤学会召集了一个工作组,针对 5 个关键问题,重点讨论了 BCC 和 cSCC 确定性和术后 RT 的适应症,以及剂量分割方案、靶区、治疗计划的基本方面、放射治疗方式的选择以及全身治疗与放射治疗联合的作用。建议基于系统文献回顾,并使用预先确定的共识制定方法和证据质量和建议强度分级系统创建。
该指南建议对不符合手术条件的 BCC 和 cSCC 患者进行确定性 RT 作为主要治疗方法,同时在那些充分切除可能导致不满意的美容或功能结果的情况下,有条件地推荐 RT,并强调共同决策。在术后情况下,提供了许多在充分切除后进行 RT 的适应症,并区分了 BCC 和 cSCC 之间的建议强度。一个关键问题是确定区域淋巴结照射的适应症。工作组建议了一系列适用于确定性和术后场景中原发和淋巴结体积治疗的适当剂量分割方案。该指南还反对在辅助 RT 中同时使用卡铂,并在治疗可能需要升级的不可切除原发性疾病时,有条件地推荐使用全身治疗。
由于缺乏高质量证据,RT 在 BCC 和 cSCC 管理中的作用一直难以确定。本文件综合了现有证据,为最常见的临床情况制定了实践指南。我们鼓励从业者让患者参与前瞻性试验,并尽可能以多学科的方式提供护理。